SCHEMBL3283552

SCHEMBL3283552

Cc1ccc(NCCCN2CC3CN(S(=O)(=O)c4ccc(F)cc4Cl)CC3C2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.42
EPHX2 P34913 4/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 1/20 0.41
HTR6 P50406 1/20 0.39
BRD4 O60885 1/20 0.39
FKBP1A P62942 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 2/20 0.38
MAPK1 P28482 1/20 0.38
MITF O75030 1/20 0.38
RAB9A P51151 2/20 0.38
FAAH O00519 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283550 0.84 SMN1; SMN2 (0.49) EPHX2MAPTSMN1; SMN2HTTTP53
SCHEMBL4692449 0.82 ALDH1A1 (0.46) EPHX2ALDH1A1MAPTGAAFKBP1A
SCHEMBL3283683 0.82 MAPT (0.47) ALDH1A1MAPTGAAHTR6FKBP1A
SCHEMBL4694435 0.82 P2RX7 (0.47) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL13326676 0.81 ALDH1A1 (0.41) ALDH1A1MAPTGAAFKBP1ASMN1; SMN2
SCHEMBL4692704 0.80 HCRTR1 (0.49) ALDH1A1MAPTGAASMN1; SMN2HTT
SCHEMBL4693295 0.79 ALDH1A1 (0.48) ALDH1A1MAPTGAASMN1; SMN2HTT
SCHEMBL4692715 0.79 HCRTR1 (0.43) ALDH1A1MAPTGAASMN1; SMN2HTT
SCHEMBL4692947 0.79 CPS1 (0.41) ALDH1A1MAPTGAASMN1; SMN2HTT
SCHEMBL4690883 0.79 NR1H4 (0.41) ALDH1A1MAPTGAASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP claimed
US-7714018-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US disclosed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014767-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 CCR1 12/4885EPHX2 2092/4885ALDH1A1 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.